Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 15428 in total
Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Approved
Investigational
Matched Categories: … Heparin and similars …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains...
Approved
Investigational
Matched Description: … regions of the VH genes Cor (1) and Cess (2). ... Synagis is a composite of human (95%) and murine (5%) antibody sequences. ... 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered...
Approved
Matched Iupac: … 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)(phenyl)methyl]piperazine …
Matched Description: … in the treatment of nausea and vomiting during pregnancy. ... It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. ... Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging …
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Description: … tPA and plasmin within the fibrinolytic pathway. ... Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. ... The primary function of endogenous C1INH is to regulate the activation of the complement and contact …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Insulin beef has been discontinued in the US and Canada since 2017.
Approved
Matched Description: … Insulin beef has been discontinued in the US and Canada since 2017.[L10827] …
Matched Categories: … Alimentary Tract and Metabolism ... Insulins and Analogues for Injection, Fast-Acting …
Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Iupac: … 1-methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole …
Matched Description: … trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and ... [nifurtimox]/[eflornithine] combination therapy (NECT), though [melarsoprol] is highly toxic and each ... meningoencephalitic) stage in which patients experience progressively worsening neurological symptoms and
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Approved
Matched Description: … A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Matched Description: … Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Dopamine And Norepinephrine Reuptake Inhibitors ... Psychostimulants, Agents Used for ADHD and Nootropics …
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … those of the skin, lung, kidneys, and liver. ... [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - ... [A234379] Agents acting on the PD-1 pathway, such as [nivolumab] and [pembrolizumab], facilitate endogenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Approved
Illicit
Withdrawn
Matched Description: … Ethchlorvynol is a sedative and hypnotic drug. ... It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance …
Matched Categories: … Hypnotics and Sedatives …
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and
Matched Categories: … Alimentary Tract and Metabolism …
Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now...
Approved
Matched Description: … patients in the European Union, Brazil, and South Korea. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C ... It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Silver nitrate is an inorganic compound with the chemical formula AgNO3. In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. It is often used as a precursor to other silver-containing compounds. It is used in making photographic films, and in laboratory setting as a staining agent...
Approved
Investigational
Matched Description: … in PAGE gels and in scanning electron microscopy. ... It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization …
Matched Categories: … Antiseptics and Disinfectants …
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a ... rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Approved
Investigational
Matched Iupac: … 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene …
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and ... symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and ... non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas …
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Iupac: … 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide …
Matched Description: … ., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke …
Matched Categories: … Genito Urinary System and Sex Hormones ... Antiinflammatory and Antirheumatic Products ... Gynecological Antiinfectives and Antiseptics ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Displaying drugs 751 - 775 of 15428 in total